Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-Gboxin in Glioblastoma and Diffuse Midline Glioma
NCT06806228Phase 1Suspended
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of s-gboxin in glioblastoma (GBM), diffuse midline glioma (DMG), Gliosarcoma (GS) and 1 more. Primary endpoint: Brain tumor metabolism as measured by PET and MRI at 6 months. Started May 2026; status: suspended.
02
Drugs
s-gboxin
03
Conditions
glioblastoma (GBM)diffuse midline glioma (DMG)Gliosarcoma (GS)giant cell glioblastoma (GC-GBM)
Beyond the preview
Go deeper on NCT06806228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806228.